The median survival in the S100B-, MIA-, LDH-, or PET/CT-positive groups was 29.7 months (95% CI not determinable), 16.4 months (95% CI, 1.5 to 31.3), 16.4 months (6.7 to 26.1) or 43.87 months (19.6 to 68.1) (Table 4), indicating that in patients with truly positive tumor markers the survival is shorter, compared with patients who are positive in PET/CT only. This evidence concerns the gene S100B and neoplasm.